(Q35768809)

10 August 2017

title

Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects (English)

1 reference

10 August 2017

1 reference

1 reference

Nassr Nassr

1

1 reference

10 August 2017

Gezim Lahu

2

1 reference

10 August 2017

Oliver von Richter

3

1 reference

10 August 2017

Felix Reutter

4

1 reference

10 August 2017

Dietrich Knoerzer

5

1 reference

10 August 2017

Karl Zech

6

1 reference

10 August 2017

Katharina A Erb

7

1 reference

10 August 2017

Barbara Schug

8

1 reference

10 August 2017

Henning Blume

9

1 reference

10 August 2017

Robert Hermann

10

1 reference

10 August 2017

language of work or name

English

0 references

publication date

29 September 2006

1 reference

British Journal of Clinical Pharmacology

10 August 2017

published in

1 reference

10 August 2017

volume

63

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

365-370

1 reference

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease

10 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1859981

Roflumilast Altana Pharma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1859981

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1859981

First-pass metabolism of midazolam by the human intestine.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1859981

Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1859981

Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1859981

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

12 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02762.X

The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02762.X

Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02762.X

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02762.X

Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02762.X

CYP3A activity in European American and Japanese men using midazolam as an in vivo probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02762.X

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02762.X

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02762.X

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02762.X

Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1859981

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1859981

Oral midazolam-grapefruit juice drug interaction

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1859981

Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1859981

10.1111/J.1365-2125.2006.02762.X

25 September 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

1 reference